Blurbs

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Airsculpt Technologies, Inc. (AIRS) and Cara Therapeutics (CARA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascendis Pharma (ASNDResearch Report), Airsculpt Technologies, Inc. (AIRSResearch Report) and Cara Therapeutics (CARAResearch Report) with bullish sentiments.

Ascendis Pharma (ASND)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Ascendis Pharma today and set a price target of $117.00. The company’s shares closed last Friday at $102.18, close to its 52-week low of $101.04.

According to TipRanks.com, Moussatos ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.7% and a 29.8% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, BioMarin Pharmaceutical, and Aquestive Therapeutics.

Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $168.00, representing a 64.4% upside. In a report issued on February 28, Citigroup also initiated coverage with a Buy rating on the stock with a $187.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Airsculpt Technologies, Inc. (AIRS)

Leerink Partners analyst Whit Mayo reiterated a Buy rating on Airsculpt Technologies, Inc. today and set a price target of $27.00. The company’s shares closed last Friday at $13.28.

According to TipRanks.com, Mayo is a 4-star analyst with an average return of 8.2% and a 56.2% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Privia Health Group, Oak Street Health, and Acadia Healthcare.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Airsculpt Technologies, Inc. with a $24.50 average price target.

Cara Therapeutics (CARA)

Needham analyst Joseph Stringer reiterated a Buy rating on Cara Therapeutics today and set a price target of $26.00. The company’s shares closed last Friday at $12.09, close to its 52-week low of $9.63.

According to TipRanks.com, Stringer ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -23.9% and a 24.8% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Phathom Pharmaceuticals, and Lexicon Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cara Therapeutics with a $26.25 average price target, implying an 117.1% upside from current levels. In a report issued on March 8, J.P. Morgan also upgraded the stock to Buy with a $20.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ASND:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos